Analyst Research

Report Title Price
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

BioScrip Inc Comments On Long Term EBITDA Guidance; Reaffirms Long Term Revenue Guidance-Conference Call


Tuesday, 24 Sep 2013 07:00am EDT 

BioScrip Inc announced that it is targeting on a longer-term adjusted EBITDA based post corporate at 10% to 12% EBITDA contribution range. Based on expanded footprint, the payer contracts and the market forces, the Company believe it can continue to grow revenue in the double digits over the long term. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $840.18 million and EBITDA of $57.55 million for fiscal 2013; revenue of $1.015 billion and EBITDA of $80.56 million for fiscal 2014. 

Company Quote

7.39
0.01 +0.14%
11 Jul 2014